Pharmaceutical giant AstraZeneca PLC (AZN) said Tuesday that a recent trial of Bydureon met the primary safety objectives to not increase cardiovascular risk for patients with Type-2 diabetes.
However, Astra said that while cardiovascular events were observed in the trial, the object of reducing cardiovascular risk wasn't statistically significant.
Continue Reading Below
-Write to Ian Walker at firstname.lastname@example.org; @IanWalk40289749
(END) Dow Jones Newswires
May 23, 2017 02:34 ET (06:34 GMT)